Institutional performance in application of the FAB classification of acute leukemia. The southwest oncology group experience

David R. Head(University of Southern California), John J. Hutton(The University of Texas at San Antonio), Charles A. Coltman(Wilford Hall Ambulatory Surgical Center), Catherine Craven(University of Utah), Lizardo Cerezo(Orlando Regional Medical Center), Henry E. Wilson(The Ohio State University), Robert J. Hartsock(Allegheny General Hospital), Richard A. Savage(Cleveland Clinic), John H. Saiki(University of New Mexico), John N. Bickers(Louisiana State University), Francis S. Morrison(Jackson Memorial Hospital), Thomas A. Hosty(Oklahoma City University)
Cancer
May 1, 1985
10.1002/1097-0142(19850501)55:9<1979::aid-cncr2820550925>3.0.co;2-#
Cited by 27

Related Papers

Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study
|Blood|2000|1.6k
Age and acute myeloid leukemia
|Blood|2006|1.4k
Acute Myeloid Leukemia in the Elderly: Assessment of Multidrug Resistance (MDR1) and Cytogenetics Distinguishes Biologic Subgroups With Remarkably Distinct Responses to Standard Chemotherapy. A Southwest Oncology Group Study
|Blood|1997|869
Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia.
|Journal of Clinical Oncology|1990|786
Acute Myeloid Leukemia in Children Treated with Epipodophyllotoxins for Acute Lymphoblastic Leukemia
|New England Journal of Medicine|1991|722